glp-1 users taking more share of food, beverage market GLP-1 users biggest mistake… ❓

We design the study with the exact same strict rules as a traditional trial, like who gets included, how they are matched, and how we measure success, but we apply these rules to historical medical records, Xiong said

Semaglutide is losing patent exclusivity in over 80 countries this year, with several drugmakers including Dr Reddys, Sun Pharma, Biocon and Ajanta Pharma targeting both regulated and emerging markets

Opioid Use Disorder Outcomes In another study by Wang, Volkow, and colleagues, which included roughly 33,000 individuals with Type 2 diabetes and opioid use disorder, semaglutide was associated with a 42-68% lower risk of opioid overdoses compared to other diabetes medications during the 1-year follow-up period (Wang et al., 2024b)

Users are actively seeking products higher in protein, fiber, and healthy fats while purchases of items high in carbohydrates and sugar are declining